Yesterday’s posting may have fooled some (I hope not so) but nevertheless contained some truths that would not  surprise many of those working in the field. Later that day, Bloomberg published an interesting piece about Pre-Exposure Prophylaxis (PrEP) and the forthcoming results of several clinical trials testing the approach.
On the outcomes of PrEP and expectated financial returns for the Pharmaceutical industry, Simeon Bennett and Tom Randall quoted Boston-based Josh Schimmer, an analyst at Leerink Swann & Co saying that “The approach may help curb the AIDS pandemic in poor …

peripheries has moved to a new webhost! Expect a few hiccups while files and links are being updated. Posting will resume shortly. In the meantime please update your bookmarks, favorites, and blogroll!

Rating 3.00 out of 5